Association of Ibrutinib Treatment With Bleeding Complications in Cutaneous Surgery

Parra, Cindy; Newsom, Emily; Lee, Erica H.; Allan, John N.; Minkis, Kira

doi:10.1001/jamadermatol.2017.1877

Cited by 13 publications

(12 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Shatzel et al recommend against taking fish oil while on ibrutinib [9]. described two patients on ibrutinib therapy who had post-operative bleeding complications after Mohs surgery to remove facial SCC [11]. The platelet counts were in the normal range for both patients at the time of surgery.…”

Section: Case Discussionmentioning

confidence: 99%

Bleeding complication following a shave biopsy in a patient taking ibrutinib

Esfandiari¹,

Bombardier²,

Pierson³

2022

DOJ

View full text Add to dashboard Cite

Section: Case Discussionmentioning

confidence: 99%

Bleeding complication following a shave biopsy in a patient taking ibrutinib

Esfandiari¹,

Bombardier²,

Pierson³

2022

DOJ

View full text Add to dashboard Cite

“…Resolution of complications was reported by day 10 in both cases. Given the increased bleeding risk associated with ibrutinib in a patient population with a greater bleeding risk at baseline, it is suggested that dermatologists and dermatologic surgeons work closely with hematologists to consider withholding ibrutinib treatment prior to surgical procedures 78 …”

Section: Targeted Therapiesmentioning

confidence: 99%

“…Given the increased bleeding risk associated with ibrutinib in a patient population with a greater bleeding risk at baseline, it is suggested that dermatologists and dermatologic surgeons work closely with hematologists to consider withholding ibrutinib treatment prior to surgical procedures. 78 Idelalisib Idelalisib inhibits the delta-isoform of phosphatidylinositol-3 kinases (PI3K), a critical signal transduction pathway restricted to the hematopoietic lineage. 30 It is FDA approved for combination therapy with rituximab in relapsed CLL.…”

Section: Bleedingmentioning

confidence: 99%

Chronic lymphocytic leukemia and the skin: implications for the dermatologist

et al. 2021

View full text Add to dashboard Cite

B-cell chronic lymphocytic leukemia (CLL) is the most prevalent leukemia in the United States, and its diagnosis can have many dermatologic implications. For one, the cutaneous manifestations of CLL include several entities, most notably leukemia cutis, eosinophilic dermatosis of hematologic malignancy, and a heightened risk of skin infections.Additionally, CLL patients are at an increased risk of secondary malignancies, most commonly of the skin. Furthermore, a number of commonly utilized treatments for CLL have cutaneous implications which should be considered in the interdisciplinary management of CLL patients. In this review, we will provide an update on the diverse cutaneous manifestations of CLL and CLL-directed therapies in order to help guide dermatologic management of this increasingly prevalent patient population. Key points• B-cell chronic lymphocytic leukemia is the most prevalent leukemia in the United States and has many associated dermatologic implications.• Dermatologists should consider primary leukemic infiltration, increased incidence and severity of secondary cutaneous malignancies, and the cutaneous manifestations of commonly utilized treatments when managing this patient population. Diagnosis of oncohematologic diseaseRecurrent episodes of pruritic papules, nodules, urticarial plaques, or vesiculobullous eruptions, refractory to standard treatment Eosinophilic infiltrate on histopathology Exclusion of other causes of tissue eosinophilia

show abstract

“…Although ibrutinib is not usually considered on presurgical proformas, its bleeding risk exceeds that of oral anticoagulants, and complications have been reported. 4,7 A practical consideration from our case is that treatment discontinuation 3-7 days before and after surgery should be considered in liaison with Haematology colleagues. 4,7…”

mentioning

confidence: 99%

“…4,7 A practical consideration from our case is that treatment discontinuation 3-7 days before and after surgery should be considered in liaison with Haematology colleagues. 4,7…”

mentioning

confidence: 99%